Delivery Order SPE2DB20D3505-SPE2DB25FU4F1

Award Date 4/16/25
Potential Completion Date 4/17/25
Potential Value $4.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $29,500.48, is for the supply of the diabetes medication Mounjaro (tirzepatide) 7.5 mg/0.5 mL pens. The contract has a period of performance through May 1, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the diabetes medication Mounjaro (Tirzepatide) 15 mg/0.5 ml pens. The contract has a firm fixed price of $4,590.11 and a period of performance through May 5, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $4,558.18, is for the supply of the diabetes medication Mounjaro (tirzepatide) 5 mg/0.5 mL pens. The contract has an ultimate completion date of April 11, 2025 and is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Mounjaro (tirzepatide) 10 mg/0.5 ml pens, a diabetes medication. The contract is a firm fixed price delivery order with a ceiling value of $1,843.66 and a period of performance through May 1, 2025. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of the diabetes medication Mounjaro (tirzepatide) 7.5 mg/0.5 ml pens, with a ceiling value of $11,093.27 and a period of performance through April 16, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the diabetes medication Mounjaro (Tirzepatide) 10 mg/0.5 ml pens. The contract has a firm fixed price of $5,301.99 and a period of performance through April 11, 2025. It is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The $12,871.11 firm-fixed-price contract is for the delivery of the diabetes medication Mounjaro (tirzepatide) 7.5 mg/0.5 ml pens. The contract has an ultimate completion date of April 24, 2025 and is not designated as a set-aside. AmerisourceBergen is a critical supplier of pharmaceutical products and medical supplies to various government...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the diabetes medication Mounjaro (tirzepatide) 10 mg/0.5 ml pens. The contract has a ceiling value of $2,629.79 and a period of performance ending on May 1, 2025. It is a firm-fixed-price contract, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,038.12, is for the supply of Mounjaro (tirzepatide) 10 mg/0.5 ml pens. It is a firm fixed-price, non-set-aside contract with a performance period through May 5, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The contract is for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 ml pens, a medication used to treat diabetes. The contract has a ceiling value of $2,808.77 and a period of performance through May 12, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen...
  • SPE2DB20D3505
    Indefinite Delivery Contract
  • SPE2DB20D3505-SPE2DB25FU4F1
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $4,418.73, is for the supply of the diabetes medication Mounjaro (tirzepatide) 7.5 mg/0.5 mL pens. The contract has an ultimate completion date of April 17, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle for federal agencies, including the Defense Health Agency and U.S. Coast Guard, through December 2026. This delivery order is not set aside and represents open competition.

Generated 7/16/25, 12:30 PM